Humanigen Submits Phase III Protocol Synopsis to FDA for Lenzilumab for Coronavirus Treatment

March 27, 2020

David J. Kovacs, Formerly at Citigroup, Joins Humanigen as COVID-19 Head of Public Policy

March 24, 2020

Humanigen Planning Phase III Study of Coronavirus Treatment

March 20, 2020

Humanigen’s Lenzilumab as a Potential Therapeutic for Lung Damage Arising from Coronavirus

March 9, 2020

Humanigen Adds to Board of Directors

December 16, 2019

Humanigen’s GM-CSF Knockout Data Presented at the 2019 Annual Meeting of American Society of Hematology Receives Award

December 11, 2019

Humanigen Terminates Exploration of Potential Rights Offering

December 2, 2019

Humanigen to Present at the 2019 Stifel Healthcare Conference

November 15, 2019

Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next Generation EphA3-CAR-T

November 12, 2019

Humanigen Announces Two Lenzilumab Abstracts Accepted for Presentation at 2019 Annual Meeting of American Society of Hematology

November 6, 2019

  • Twitter

©2020 Humanigen, Inc.  All rights reserved